CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a new research paper entitled "Point-of-Care EEG Artificial Intelligence Measure of Seizure Burden Associates with Clinical Outcome at Discharge" was published in Critical Care Medicine (CCM),1 the official, peer-reviewed scientific journal of the Society of Critical Care Medicine (SCCM).
The landmark study provides evidence that Ceribell's Clarity® artificial intelligence (AI) algorithm, specifically its measure of seizure burden, is correlated with a patient's functional outcomes at discharge. The findings further support Ceribell's leadership in AI-powered Point-of-Care EEG (POC EEG), addressing a critical unmet need for rapid, actionable neurodiagnostics in the Emergency Department (ED) and Intensive Care Unit (ICU).
Key Research Findings:
The study analyzed data from 359 adult patients across three academic sites—Yale School of Medicine, Massachusetts General Hospital, and The University of New Mexico School of Medicine—where both Ceribell POC EEG and nearly 24/7 conventional EEG were available. Building upon the foundational SAFER-EEG (Seizure Assessment and Forecasting With Efficient Rapid-EEG) study, originally published in the peer-reviewed journal Neurology (July 2024),2 the new analysis reveals:
- AI Measure of Seizure Burden Linked to Outcomes: Higher seizure burden detected by Ceribell's Clarity algorithm was associated with increased severe disability and poorer functional outcomes at the time of discharge. Compared to patients with 0% seizure burden, those with a peak 5-minute seizure burden greater than or equal to 90% at any point during EEG monitoring were 3.4 times more likely to experience death or severe disability as measured by a modified Rankin Scale (mRS) score equal to or higher than four, at discharge.
- Time is Brain: Risk escalates with ongoing seizure activity. Each additional hour of Clarity-assessed seizure in the EEG recording is associated with nearly a two-fold increase in risk of severe disability or death (adjusted odds ratio = 1.98).
- Clinical Utility: Clarity is the first validated bedside tool to demonstrate a strong "dose-response" relationship between AI-estimated seizure burden and functional outcomes of severe disability or death, even after adjusting for multiple clinical covariates. Prompt recognition and management of seizure burden may be critical to improving outcomes in acute care.